2022

Schwartze, J. T., Havenga, M., Bakker, W. A. M., Bradshaw, A. C. and Nicklin, S. A. (2022) Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 100(6), pp. 875-901. (doi: 10.1007/s00109-022-02208-0) (PMID:35606652) (PMCID:PMC9126699)

2021

Bates, E. A. et al. (2021) In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses, 13(8), 1483. (doi: 10.3390/v13081483)

2019

Noonan, J., Grassia, G., MacRitchie, N., Garside, P. , Guzik, T. J., Bradshaw, A. C. and Maffia, P. (2019) A novel triple-cell two-dimensional model to study immune-vascular interplay in atherosclerosis. Frontiers in Immunology, 10, 849. (doi: 10.3389/fimmu.2019.00849) (PMID:31068936) (PMCID:PMC6491724)

Low, E. L., Baker, A. H. and Bradshaw, A. C. (2019) TGFβ, smooth muscle cells and coronary artery disease: a review. Cellular Signalling, 53, pp. 90-101. (doi: 10.1016/j.cellsig.2018.09.004) (PMID:30227237) (PMCID:PMC6293316)

Schwartze, J. T., Low, E. L. and Bradshaw, A. C. (2019) TGF-β in vascular pathobiology. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 137-148. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_13)

2018

Uusi-Kerttula, H. et al. (2018) Ad5NULL-A20: a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research, 24(17), pp. 4215-4224. (doi: 10.1158/1078-0432.CCR-18-1089) (PMID:29798908)

Noonan, J. et al. (2018) In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 8(22), pp. 6195-6209. (doi: 10.7150/thno.28665) (PMID:30613292) (PMCID:PMC6299693)

2017

Lopez-Gordo, E., Doszpoly, A., Duffy, M. R., Coughlan, L., Bradshaw, A. C. , White, K. M., Denby, L., Nicklin, S. A. and Baker, A. H. (2017) Defining a novel role for the coxsackie and adenovirus receptor in human adenovirus serotype 5 transduction in vitro in the presence of mouse serum. Journal of Virology, 91(12), e02487-16. (doi: 10.1128/JVI.02487-16) (PMID:28381574) (PMCID:PMC5446653)

Deng, L., Baker, A. H. and Bradshaw, A. C. (2017) MicroRNA delivery strategies to the lung in a model of pulmonary hypertension. In: Ishikawa, K. (ed.) Cardiac Gene Therapy: Methods and Protocols. Series: Methods in molecular biology (1521). Humana Press: New York, NY, pp. 325-338. ISBN 9781493965861 (doi: 10.1007/978-1-4939-6588-5_23)

2016

Deng, L., Bradshaw, A. C. and Baker, A. H. (2016) Role of noncoding RNA in vascular remodelling. Current Opinion in Lipidology, 27(5), pp. 439-448. (doi: 10.1097/MOL.0000000000000336) (PMID:27472407)

2015

Deng, L. et al. (2015) MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circulation Research, 117(10), pp. 870-883. (doi: 10.1161/CIRCRESAHA.115.306806) (PMID:26311719) (PMCID:PMC4620852)

2013

Bradshaw, A. C. and Baker, A. H. (2013) Gene therapy for cardiovascular disease: perspectives and potential. Vascular Pharmacology, 58(3), pp. 174-181. (doi: 10.1016/j.vph.2012.10.008)

Parker, A. L., Bradshaw, A. C. , Alba, R., Nicklin, S. A. and Baker, A. H. (2013) Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. (eds.) Adenovirus: Methods and Protocols [3rd.]. Series: Methods in molecular biology (1089). Humana Press, pp. 45-59. ISBN 9781627036788 (doi: 10.1007/978-1-62703-679-5_3)

White, K. M., Alba, R., Parker, A. L., Wright, A. F., Bradshaw, A. C. , Delles, C. , McDonald, R. A. and Baker, A. H. (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery, 8(183), (doi: 10.1186/1749-8090-8-183)

2012

Bradshaw, A. C. , Coughlan, L., Miller, A. M.., Nicklin, S. A. , Baker, A. H., Alba, R. and van Rooijen, N. (2012) Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release, 164(3), pp. 394-402. (doi: 10.1016/j.jconrel.2012.05.025)

Coughlan, L. et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy, 20(12), pp. 2268-2281. (doi: 10.1038/mt.2012.162) (PMID:22929662) (PMCID:PMC3514487)

Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. (2012) Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine, 7(2), pp. 271-288. (doi: 10.2217/nnm.11.186)

Alba, R., Bradshaw, A.C. , Mestre-Francés, N., Verdier, J.-M., Henaff, D. and Baker, A.H. (2012) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Therapy, 19(1), pp. 109-113. (doi: 10.1038/gt.2011.87)

2011

Duffy, M.R., Bradshaw, A.C. , Parker, A.L., McVey, J.H. and Baker, A.H. (2011) A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus/FX complexes. Journal of Virology, 85(20), pp. 10914-10919. (doi: 10.1128/JVI.05382-11)

2010

Alba, R. et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 14(116), pp. 2656-2664. (doi: 10.1182/blood-2009-12-260026)

Bradshaw, A.C. , Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., Kahari, V.M., Nicklin, S.A. and Baker, A.H. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens, 6(10), e1001142. (doi: 10.1371/journal.ppat.1001142)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C. , Mcneish, I.A. , Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi: 10.3390/v2102290) (PMID:21994621) (PMCID:PMC3185574)

2009

Alba, R. et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 114(5), pp. 965-971. (doi: 10.1182/blood-2009-03-208835)

Articles

Schwartze, J. T., Havenga, M., Bakker, W. A. M., Bradshaw, A. C. and Nicklin, S. A. (2022) Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 100(6), pp. 875-901. (doi: 10.1007/s00109-022-02208-0) (PMID:35606652) (PMCID:PMC9126699)

Bates, E. A. et al. (2021) In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses, 13(8), 1483. (doi: 10.3390/v13081483)

Noonan, J., Grassia, G., MacRitchie, N., Garside, P. , Guzik, T. J., Bradshaw, A. C. and Maffia, P. (2019) A novel triple-cell two-dimensional model to study immune-vascular interplay in atherosclerosis. Frontiers in Immunology, 10, 849. (doi: 10.3389/fimmu.2019.00849) (PMID:31068936) (PMCID:PMC6491724)

Low, E. L., Baker, A. H. and Bradshaw, A. C. (2019) TGFβ, smooth muscle cells and coronary artery disease: a review. Cellular Signalling, 53, pp. 90-101. (doi: 10.1016/j.cellsig.2018.09.004) (PMID:30227237) (PMCID:PMC6293316)

Uusi-Kerttula, H. et al. (2018) Ad5NULL-A20: a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research, 24(17), pp. 4215-4224. (doi: 10.1158/1078-0432.CCR-18-1089) (PMID:29798908)

Noonan, J. et al. (2018) In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 8(22), pp. 6195-6209. (doi: 10.7150/thno.28665) (PMID:30613292) (PMCID:PMC6299693)

Lopez-Gordo, E., Doszpoly, A., Duffy, M. R., Coughlan, L., Bradshaw, A. C. , White, K. M., Denby, L., Nicklin, S. A. and Baker, A. H. (2017) Defining a novel role for the coxsackie and adenovirus receptor in human adenovirus serotype 5 transduction in vitro in the presence of mouse serum. Journal of Virology, 91(12), e02487-16. (doi: 10.1128/JVI.02487-16) (PMID:28381574) (PMCID:PMC5446653)

Deng, L., Bradshaw, A. C. and Baker, A. H. (2016) Role of noncoding RNA in vascular remodelling. Current Opinion in Lipidology, 27(5), pp. 439-448. (doi: 10.1097/MOL.0000000000000336) (PMID:27472407)

Deng, L. et al. (2015) MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circulation Research, 117(10), pp. 870-883. (doi: 10.1161/CIRCRESAHA.115.306806) (PMID:26311719) (PMCID:PMC4620852)

Bradshaw, A. C. and Baker, A. H. (2013) Gene therapy for cardiovascular disease: perspectives and potential. Vascular Pharmacology, 58(3), pp. 174-181. (doi: 10.1016/j.vph.2012.10.008)

White, K. M., Alba, R., Parker, A. L., Wright, A. F., Bradshaw, A. C. , Delles, C. , McDonald, R. A. and Baker, A. H. (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery, 8(183), (doi: 10.1186/1749-8090-8-183)

Bradshaw, A. C. , Coughlan, L., Miller, A. M.., Nicklin, S. A. , Baker, A. H., Alba, R. and van Rooijen, N. (2012) Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release, 164(3), pp. 394-402. (doi: 10.1016/j.jconrel.2012.05.025)

Coughlan, L. et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy, 20(12), pp. 2268-2281. (doi: 10.1038/mt.2012.162) (PMID:22929662) (PMCID:PMC3514487)

Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. (2012) Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine, 7(2), pp. 271-288. (doi: 10.2217/nnm.11.186)

Alba, R., Bradshaw, A.C. , Mestre-Francés, N., Verdier, J.-M., Henaff, D. and Baker, A.H. (2012) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Therapy, 19(1), pp. 109-113. (doi: 10.1038/gt.2011.87)

Duffy, M.R., Bradshaw, A.C. , Parker, A.L., McVey, J.H. and Baker, A.H. (2011) A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus/FX complexes. Journal of Virology, 85(20), pp. 10914-10919. (doi: 10.1128/JVI.05382-11)

Alba, R. et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 14(116), pp. 2656-2664. (doi: 10.1182/blood-2009-12-260026)

Bradshaw, A.C. , Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., Kahari, V.M., Nicklin, S.A. and Baker, A.H. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens, 6(10), e1001142. (doi: 10.1371/journal.ppat.1001142)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C. , Mcneish, I.A. , Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi: 10.3390/v2102290) (PMID:21994621) (PMCID:PMC3185574)

Alba, R. et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 114(5), pp. 965-971. (doi: 10.1182/blood-2009-03-208835)

Book Sections

Schwartze, J. T., Low, E. L. and Bradshaw, A. C. (2019) TGF-β in vascular pathobiology. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 137-148. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_13)

Deng, L., Baker, A. H. and Bradshaw, A. C. (2017) MicroRNA delivery strategies to the lung in a model of pulmonary hypertension. In: Ishikawa, K. (ed.) Cardiac Gene Therapy: Methods and Protocols. Series: Methods in molecular biology (1521). Humana Press: New York, NY, pp. 325-338. ISBN 9781493965861 (doi: 10.1007/978-1-4939-6588-5_23)

Parker, A. L., Bradshaw, A. C. , Alba, R., Nicklin, S. A. and Baker, A. H. (2013) Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. (eds.) Adenovirus: Methods and Protocols [3rd.]. Series: Methods in molecular biology (1089). Humana Press, pp. 45-59. ISBN 9781627036788 (doi: 10.1007/978-1-62703-679-5_3)